



UNIDADE DE  
FARMACOVIGILÂNCIA  
DOS AÇORES




# **Effectiveness of Additional Risk Minimization Measures when using baricitinib (Risk-Bari) - Preliminary analysis**



# Results


Respondents demonstrated that they were aware of most of the risks addressed by the aRMMs, with the exception of malignant neoplasms (24.8% of respondents answered incorrectly, and 18.0% were unaware of this information).

Graphic 1: Physicians' knowledge of the risks mentioned in Baricitinib aRMM




Only 27.9% of the respondents were aware of aRMMs when answering the questionnaire in this study and 63.5% recognized the Pharmaceutical Industry as the primary source of information, followed by symposia/ conferences (39.9%) and scientific journals (37.9%).

Graphic 2: Where did you learn about aRMM?




Most physicians (65.0%) considered educational materials accessible, while 52.6% of respondents are unaware that they are available through the national medicines database (INFOMED).

**Graphic 3: Do you consider that aRMM materials are accessible to physicians?**




**Graphic 4: Are you aware that the materials are available on INFOMED?**



Regarding adherence to educational materials, we verified the following:

**Graphic 5: What aRMM did you use?**



The three main barriers to implementing aRMMs identified by respondents were:

- lack of time (39.2%),
- insufficient dissemination (32.1%), and
- difficulty communicating with the patient (12.3%).